Correlation between chemotherapy cycles and performance status based on ECOG in non-small cell lung cancer patients

Main Article Content

NOVITA ANDAYANI
Diana F Syafni
Mirfandi Amirsyah
Yunita Arliny
Rima Novirianthy
Murtaza

Abstract

Background: The prevalence of lung cancer incidence is 14.3% in men and 8.4% in women. Smoking is one of the causes of lung cancer. Chemotherapy is a treatment for NSCLC and affects to the performance status patients.


Aim: This study is to determine the relationship between chemotherapy cycles and performance status based on ECOG in non-small cell carcinoma (NSCLC) lung cancer patients at dr. Zainoel Abidin Banda Aceh in 2017-2020.


Method: This is an observational analytic study with cross sectional design with total sampling method and data sourced from medical records as many as 164 subjects.


Result: The results showed that 57% of NSCLC patients after chemotherapy had a stable performance status while the other 41% decreased. The carboplatin + paclitaxel regimen is the most widely used regimen (43%) and shows average PFS < 1 year dan OS < 2 years.


Conclusion: Based on bivariate analysis using the Spearman method, obtained p-value <0.05 with an R value of 0.367 which indicates there is a relationship between chemotherapy cycles and performance status based on ECOG in NSCLC patients at RSUD dr. Zainoel Abidin with a low correlation coefficient.

Article Details

Section
Original Articles